US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by Galimedix Therapeutics, Inc.

News headline image
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
From Galimedix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
From Galimedix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
From Galimedix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
From Galimedix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
From Galimedix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
From Galimedix Therapeutics, Inc.
Via GlobeNewswire